Patent ID: 7534431

Claim:
A method for treating or diagnosing cancer in a subject, comprising: a) administering to said subject (i) a bispecific antibody comprising a target binding moiety that binds to a tumor-associated marker selected from the group consisting of carcinoembryonic antigen (CEA), colon-specific antigen-p (CSAp), CD4, CD5, CD8, CD14, CD15, CD19, CD20, CD22, CD40, CD40L, CD74, B7, HLA-DR, EGFR, HER 2/neu, TAG-72, EGP-1, HCG, HCG-beta, PSMA, PSA, VEGF, IL-2 and MAGE, and at least one targetable construct binding moiety that binds to a first hapten comprising HSG (histamine succinyl glycine), DTPA (diethylenetriaminepentaacetic acid) or Tscg-Cys (thiosemi-carbazonylglyoxylcysteine); (ii) a targetable construct comprising Ac-Lys(DTPA)-Tyr-Lys(DTPA)-Lys(Tscg-Cys)-NH 2 (SEQ TD NO:1), or DTPA-Gln-Ala-Lys(HSG)-D-Tyr-Lys(HSG)-NH 2 (IMP 272), said targetable construct comprising a therapeutic or diagnostic moiety; and (iii) a clearing agent comprising one or more second antibody or antigen binding fragment thereof that binds to a second hapten comprising HSG, DTPA or Tscg-Cys, wherein said first and second haptens are orthogonal to each other and said clearing agent enhances retention of said targetable construct at a target site.